The subject of the contract is the supply of cytostatic drugs as part of separate tasks (packages), including cytostatic drugs that meet the requirements set out in the catalogues of reimbursed drugs used in chemotherapy and drug programs specified:
• in Regulation No. 17/2022/DGL of the President of the National Health Fund of 11 February 2022 on determining the conditions for concluding and implementing contracts such as hospital treatment in the field of chemotherapy.
• in Regulation No. 16/2022/DGL of the President of the National Health Fund of 11 February 2022 on determining the conditions for concluding and implementing contracts such as hospital treatment in the field of drug programs.
in the assortment and quantities specified in Annex 5 to SWZ
Package No. 1The scope of the order includes the medicines described in Annex 5 to SWZ - assortment and price form.
Package No. 2The scope of the order includes the medicines described in Annex 5 to SWZ - assortment and price form.
Package No. 3The scope of the order includes the medicines described in Annex 5 to SWZ - assortment and price form.
Package No. 4The scope of the order includes the medicines described in Annex 5 to SWZ - assortment and price form.
Package number 5The scope of the order includes the medicines described in Annex 5 to SWZ - assortment and price form.
Package number 6The scope of the order includes the medicines described in Annex 5 to SWZ - assortment and price form.